Unlocking the Growth Potential of NASDAQ:TGTX.

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if TG THERAPEUTICS INC (NASDAQ:TGTX) is suited for growth investing. Investors should of course do their own research, but we spotted TG THERAPEUTICS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

What matters for growth investors.

• With a solid Return on Equity (ROE) of 53.87%, TG THERAPEUTICS INC exemplifies its ability to generate favorable returns on shareholder investments. This metric demonstrates the company's commitment to maximizing shareholder value.
• TG THERAPEUTICS INC has exceeded EPS estimates 3 times in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• With notable 1-year revenue growth of 1.0K%, TG THERAPEUTICS INC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for future growth.
• TG THERAPEUTICS INC has demonstrated strong q2q revenue growth of 357.0%, suggesting a favorable trend in the company's financials and indicating the potential for continued expansion.
• The operating margin of TG THERAPEUTICS INC has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• With a favorable trend in its free cash flow (FCF) over the past year, TG THERAPEUTICS INC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• The quarterly earnings of TG THERAPEUTICS INC have shown a 112.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• TG THERAPEUTICS INC has seen a 329.0% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• The recent financial report of TG THERAPEUTICS INC demonstrates a 112.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• TG THERAPEUTICS INC shows accelerating EPS growth: when comparing the current Q2Q growth of 112.0% to the previous year Q2Q growth of -13.33%, we see the growth rate improving.

Fundamental Analysis Observations

ChartMill employs a sophisticated system to assign a Fundamental Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple fundamental indicators and properties.

We assign a fundamental rating of 6 out of 10 to TGTX. TGTX was compared to 572 industry peers in the Biotechnology industry. TGTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TGTX is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, TGTX could be worth investigating further for growth investing!.

For an up to date full fundamental analysis you can check the fundamental report of TGTX

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.